The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
暂无分享,去创建一个
Isao Kamae | Jalpa A Doshi | Maiwenn Al | W. Mcghan | J. Doshi | I. Kamae | S. Marx | D. Rindress | M. Al | Donna Rindress | William F McGhan | Steven E Marx
[1] A H Briggs,et al. Power and Sample Size Calculations for Stochastic Cost-Effectiveness Analysis , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[2] E. Feuer,et al. Estimating medical costs from incomplete follow-up data. , 1997, Biometrics.
[3] L. Mantovani,et al. Guidelines for Economic Evaluations in Italy: Recommendations from The Italian Group of Pharmacoeconomic Studies , 2001 .
[4] Sue Eckstein,et al. Good research practice , 2003 .
[5] B. O'brien,et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. , 2005, Health economics.
[6] W. Manning,et al. Estimating Log Models: To Transform or Not to Transform? , 1999, Journal of health economics.
[7] M. Gold,et al. Panel on cost-effectiveness in health and medicine. , 1996, Medical care.
[8] R. Willke,et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] P. McCullagh,et al. Generalized Linear Models , 1992 .
[10] J. Graf von der Schulenburg,et al. The influence of economic evaluation studies on decision making. A European survey. The EUROMET group. , 2000, Health policy.
[11] S. Stearns,et al. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. , 1996, Statistics in medicine.
[12] W. Manning,et al. The logged dependent variable, heteroscedasticity, and the retransformation problem. , 1998, Journal of health economics.
[13] John C. Hershey,et al. Carrier Screening for Cystic Fibrosis , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[14] R. Grieve,et al. Using multilevel models for assessing the variability of multinational resource use and cost data. , 2005, Health economics.
[15] G. Lu,et al. Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.
[16] B. O'brien,et al. The death of cost-minimization analysis? , 2001, Health economics.
[17] B. O'brien,et al. Cost–effectiveness analysis for multinational clinical trials , 2005, Statistics in medicine.
[18] M. Drummond,et al. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[19] Simon G Thompson,et al. Uncertainty and validation of health economic decision models. , 2009, Health economics.
[20] Jeroen P Jansen,et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[21] P. McCullagh,et al. Generalized Linear Models, 2nd Edn. , 1990 .
[22] Milton C. Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996 .
[23] M. Kelly. Addressing the issues , 2002 .
[24] M. Drummond,et al. Evaluating the BMJ guidelines for economic submissions: prospective audit of economic submissions to BMJ and The Lancet. , 1998, JAMA.
[25] N. Muszbek,et al. Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards , 2002, The European Journal of Health Economics.
[26] F. Antoñanzas,et al. Economic Analysis of Health Technologies and Programmes , 1995, PharmacoEconomics.
[27] G. Brown,et al. Analysis of costs. , 2000, Archives of ophthalmology.
[28] C. Bell,et al. The Quality of Reporting in Published Cost-Utility Analyses, 19761997 , 2000, Annals of Internal Medicine.
[29] M A Koopmanschap,et al. Analysis of costs and cost-effectiveness in multinational trials. , 2001, Health policy.
[30] Dan Greenberg,et al. Quality of Abstracts of Papers Reporting Original Cost-Effectiveness Analyses , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[31] M. Gail,et al. Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.
[32] Andrew R Willan,et al. Regression methods for cost‐effectiveness analysis with censored data , 2005, Statistics in medicine.
[33] J. Schulenburg. The Influence of Economic Evaluation Studies on Health Care Decision-Making: A European Survey , 2000 .
[34] D. Lin,et al. Proportional Means Regression for Censored Medical Costs , 2000, Biometrics.
[35] J. Hay,et al. Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES , 2003, Journal of managed care pharmacy : JMCP.
[36] Deborah M Caldwell,et al. Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.
[37] D. Lin,et al. Regression analysis of incomplete medical cost data , 2003, Statistics in medicine.
[38] M J Al,et al. Sample size calculation in economic evaluations. , 1998, Health economics.
[39] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[40] Anthony O'Hagan,et al. Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[41] Morris Meisner,et al. Power and Sample Size in Cost- Effectiveness Analysis , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.
[42] Katie Lahey,et al. Raising the Quality , 2008 .
[43] E. Walter,et al. [Guidelines for health-economic evaluations in Austria]. , 2006, Wiener medizinische Wochenschrift.
[44] D G Altman,et al. Transfer of technology from statistical journals to the biomedical literature. Past trends and future predictions. , 1994, JAMA.
[45] S. Sullivan,et al. Incorporating clinical outcomes and economic consequences into drug formulary decisions: a practical approach. , 1999, The American journal of managed care.
[46] D Polsky,et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. , 1997, Health economics.
[47] Milton C. Weinstein,et al. Recommendations for Reporting Cost-effectiveness Analyses , 1996 .
[48] J. Hutton,et al. Use of economic evaluation in decision making: what needs to change? , 2002, Value in Health.
[49] M. Drummond,et al. A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.
[50] A E Ades,et al. Expected Value of Sample Information Calculations in Medical Decision Modeling , 2004, Medical decision making : an international journal of the Society for Medical Decision Making.
[51] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[52] Anthony O'Hagan,et al. On estimators of medical costs with censored data. , 2004, Journal of health economics.
[53] A. Mcguire,et al. Estimating medical care costs under conditions of censoring. , 2004, Journal of health economics.
[54] P Fenn,et al. The Analysis of Censored Treatment Cost Data in Economic Evaluation , 1995, Medical care.
[55] A. L. Hillman,et al. Economic Analysis of Health Care Technology: A Report on Principles , 1995, Annals of Internal Medicine.
[56] A H Briggs,et al. Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses , 2001, Expert review of pharmacoeconomics & outcomes research.
[57] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[58] Nigel Rice,et al. Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[59] S. Thompson,et al. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. , 2000, Statistics in medicine.
[60] N. Olchanski,et al. Growth and quality of the cost-utility literature, 1976-2001. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[61] J. Seymour,et al. Raising the quality of cost-utility analyses: lessons learnt and still to learn. , 1999, Health policy.
[62] John Enos,et al. TRANSFER OF TECHNOLOGY , 1989 .
[63] Péter Jacsó,et al. Quality of abstracts , 1993 .
[64] Joseph C Gardiner,et al. Longitudinal analysis of censored medical cost data. , 2006, Health economics.
[65] B. McNeil,et al. Probabilistic Sensitivity Analysis Using Monte Carlo Simulation , 1985, Medical decision making : an international journal of the Society for Medical Decision Making.
[66] J Hjelmgren,et al. Health economic guidelines--similarities, differences and some implications. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[67] P W Lavori,et al. A multiple imputation strategy for clinical trials with truncation of patient data. , 1995, Statistics in medicine.
[68] A E Ades,et al. A chain of evidence with mixed comparisons: models for multi‐parameter synthesis and consistency of evidence , 2003, Statistics in medicine.
[69] Anastasios A. Tsiatis,et al. Estimating medical costs with censored data , 2000 .
[70] Daniel Polsky,et al. Economic Evaluation in Clinical Trials , 2007 .
[71] Jalpa A Doshi,et al. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[72] R. Stanford,et al. The National Health and Medical Research Council , 1937 .
[73] P. Haywood,et al. How to compare the costs and benefits: evaluation of the economic evidence , 2001 .
[74] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[75] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[76] Jan B Oostenbrink,et al. The analysis of incomplete cost data due to dropout. , 2005, Health economics.
[77] M. Drummond,et al. The lag between effectiveness and cost-effectiveness evidence of new drugs , 2003, The European Journal of Health Economics, formerly: HEPAC.
[78] Robert L Strawderman,et al. Flexible hazard regression modeling for medical cost data. , 2002, Biostatistics.
[79] S. M. Gore,et al. The Lancet's statistical review process: areas for improvement by authors , 1992, The Lancet.
[80] Sean D Sullivan,et al. Quality of clinical and economic evidence in dossier formulary submissions. , 2007, The American journal of managed care.
[81] S G Thompson,et al. Analysis and interpretation of cost data in randomised controlled trials: review of published studies , 1998, BMJ.
[82] D. Lin,et al. Linear regression analysis of censored medical costs. , 2000, Biostatistics.
[83] S. Hill,et al. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. , 2000, JAMA.
[84] M C Hornbrook,et al. Modeling risk using generalized linear models. , 1999, Journal of health economics.
[85] S. T. Buckland,et al. An Introduction to the Bootstrap. , 1994 .
[86] Richard D Riley,et al. Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. , 2007, Journal of clinical epidemiology.
[87] J. Heyse,et al. A regression-based method for estimating mean treatment cost in the presence of right-censoring. , 2000, Biostatistics.
[88] Alex J. Sutton,et al. Methods for Meta-Analysis in Medical Research , 2000 .
[89] Kimbroe J. Carter,et al. Treatment of Early-Stage Breast Cancer in the Elderly , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[90] P. Trueman,et al. Research into the use of health economics in decision making in the United Kingdom--Phase II. Is health economics 'for good or evil'? , 1999, Health policy.
[91] Michael Drummond,et al. Assessing the appropriateness of combining economic data from multinational clinical trials , 2003, Statistics in medicine.
[92] Ruth Etzioni,et al. Estimating the costs attributable to a disease with application to ovarian cancer. , 1996, Journal of clinical epidemiology.
[93] Sean D Sullivan,et al. Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies , 2003, Medical care.
[94] P. Ball. For good or evil , 2005 .
[95] R. Robinson. Economic Evaluation and Health Care Cost-effectiveness analysis , 2006 .
[96] Milton C Weinstein,et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[97] Bernie J. O'Brien,et al. In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care , 1994, Medical care.
[98] Karl Claxton,et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[99] John Cairns,et al. Multilevel models for estimating incremental net benefits in multinational studies. , 2007, Health economics.
[100] M C Weinstein,et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[101] A R Willan,et al. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. , 1996, Health economics.
[102] M. Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[103] Richard Grieve,et al. Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study. , 2006, Journal of health economics.
[104] R Robinson,et al. Costs and cost-minimisation analysis. , 1993, BMJ.
[105] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[106] Evelyn Walter,et al. Guidelines zur gesundheitsökonomischen Evaluation Konsenspapier , 2006, Wiener Medizinische Wochenschrift.
[107] A R Willan,et al. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. , 1999, Health economics.
[108] S. Thompson,et al. How should cost data in pragmatic randomised trials be analysed? , 2000, BMJ : British Medical Journal.
[109] R. Willke,et al. Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, Health economics.
[110] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[111] J. Gray,et al. The NHS economic evaluation database , 1997 .
[112] M. Sculpher,et al. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. , 2005, Health economics.
[113] M. Drummond,et al. Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .
[114] Andrew M. Jones,et al. Multilevel models and health economics. , 1997, Health economics.
[115] Dan Greenberg,et al. Bias in published cost effectiveness studies: systematic review , 2006, BMJ : British Medical Journal.
[116] L. Erickson,et al. Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications , 2008, BMC health services research.